The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery: ASPSM comparison of HIPEC with MMC vs. Oxaliplatin
Open accessAbstract
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery. METHODS: The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS). RESULTS: Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P = 0.427). CONCLUSION: These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Prospective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cohen, M. S., Al-kasspooles, M. F., Williamson, S. K., Henry, D., Broward, M., & Roby, K. F. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0669-0 · Cited by 17
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Quénet, F., Elias, D., Roca, L., Goéré, D., Ghouti, L., Pocard, M., Facy, O., Arvieux, C., Lorimier, G., Pezet, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30599-4 · Cited by 827
Self-citation
Metadata
- Authors
- Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M., Chua, T., Pelz, J., Baratti, D., Baumgartner, J. M., Berri, R., Bretcha-Boix, P., Deraco, M., Flores-Ayala, G., Glehen, O., Gomez-Portilla, A., González-Moreno, S., Goodman, M., Halkia, E., Kusamura, S., Moller, M., Passot, G., Pocard, M., Salti, G., Sardi, A., Senthil, M., Spiliotis, J., Torres-Melero, J., Turaga, K., & Trout, R.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2014-08-02
- Volume
- 110
- Issue
- 7
- Pages
- 779-785
- ISSN
- 0022-4790 (ISSN-L)
- OpenAlex
- W2099306609
- Cited by
- 163
- References
- 1
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery: ASPSM comparison of HIPEC with MMC vs. Oxaliplatin. https://app.cochat.ai/papers/10.1002/jso.23728
- The paper
- Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M., Chua, T., Pelz, J., Baratti, D., Baumgartner, J. M., Berri, R., Bretcha-Boix, P., Deraco, M., Flores-Ayala, G., Glehen, O., Gomez-Portilla, A., González-Moreno, S., Goodman, M., Halkia, E., Kusamura, S., Moller, M., . . . Trout, R. (2014). The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery: ASPSM comparison of HIPEC with MMC vs. Oxaliplatin. Journal of Surgical Oncology. https://doi.org/10.1002/jso.23728
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.